Conmed Capital Expenditures (CapEx) Growth & History (CNMD)
Conmed's capital expenditures (capex) was $19.8M for fiscal 2025.
View full Conmed company overviewConmed annual capital expenditures (capex) history
| Fiscal year | Period ended | Capital expenditures (CapEx) | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $19.8M | $6.7M | +51.38% |
| 2024 | 2024-12-31 | $13.1M | −$5.9M | −31.25% |
| 2023 | 2023-12-31 | $19.0M | −$2.8M | −12.64% |
| 2022 | 2022-12-31 | $21.8M | $6.9M | +46.54% |
| 2021 | 2021-12-31 | $14.9M | $1.9M | +14.24% |
| 2020 | 2020-12-31 | $13.0M | −$7.1M | −35.15% |
| 2019 | 2019-12-31 | $20.1M | $3.6M | +21.56% |
| 2018 | 2018-12-31 | $16.5M | $3.7M | +28.54% |
| 2017 | 2017-12-31 | $12.8M | −$1.9M | −12.95% |
| 2016 | 2016-12-31 | $14.8M | −$256,000 | −1.71% |
| 2015 | 2015-12-31 | $15.0M | −$402,000 | −2.61% |
| 2014 | 2014-12-31 | $15.4M | −$3.0M | −16.45% |
| 2013 | 2013-12-31 | $18.4M | −$3.1M | −14.34% |
| 2012 | 2012-12-31 | $21.5M | $4.0M | +22.68% |
| 2011 | 2011-12-31 | $17.6M | $2.8M | +19.14% |
| 2010 | 2010-12-31 | $14.7M | −$6.7M | −31.30% |
| 2009 | 2009-12-31 | $21.4M | — | — |
Conmed quarterly capital expenditures (capex)
| Fiscal quarter | Period ended | Capital expenditures (CapEx) | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $2.9M | −$2.8M | −48.79% |
| Q1 2026 | 2026-03-31 | $2.9M | −$887,000 | −23.47% |
| Q4 2025 | 2025-12-31 | $5.1M | $1.1M | +26.51% |
| Q3 2025 | 2025-09-30 | $5.2M | $1.8M | +51.71% |
| Q2 2025 | 2025-06-30 | $5.7M | $2.1M | +59.58% |
| Q1 2025 | 2025-03-31 | $3.8M | $1.7M | +85.70% |
| Q4 2024 | 2024-12-31 | $4.0M | −$815,000 | −16.79% |
| Q3 2024 | 2024-09-30 | $3.4M | −$2.0M | −36.61% |
| Q2 2024 | 2024-06-30 | $3.6M | −$939,000 | −20.73% |
| Q1 2024 | 2024-03-31 | $2.0M | −$2.2M | −52.16% |
| Q4 2023 | 2023-12-31 | $4.9M | −$821,000 | −14.46% |
| Q3 2023 | 2023-09-30 | $5.4M | −$1.3M | −19.62% |
| Q2 2023 | 2023-06-30 | $4.5M | −$1.2M | −20.70% |
| Q1 2023 | 2023-03-31 | $4.3M | $567,000 | +15.38% |
| Q4 2022 | 2022-12-31 | $5.7M | $2.5M | +78.04% |
| Q3 2022 | 2022-09-30 | $6.7M | $1.1M | +20.38% |
| Q2 2022 | 2022-06-30 | $5.7M | $2.7M | +90.75% |
| Q1 2022 | 2022-03-31 | $3.7M | $578,000 | +18.59% |
| Q4 2021 | 2021-12-31 | $3.2M | $39,000 | +1.24% |
| Q3 2021 | 2021-09-30 | $5.6M | $2.3M | +69.61% |
| Q2 2021 | 2021-06-30 | $3.0M | −$758,000 | −20.20% |
| Q1 2021 | 2021-03-31 | $3.1M | $284,000 | +10.05% |
| Q4 2020 | 2020-12-31 | $3.1M | −$3.0M | −49.14% |
| Q3 2020 | 2020-09-30 | $3.3M | −$1.6M | −32.49% |
| Q2 2020 | 2020-06-30 | $3.8M | −$1.2M | −24.72% |
| Q1 2020 | 2020-03-31 | $2.8M | −$1.2M | −29.76% |
| Q4 2019 | 2019-12-31 | $6.2M | $1.4M | +30.17% |
| Q3 2019 | 2019-09-30 | $4.9M | $409,000 | +9.17% |
| Q2 2019 | 2019-06-30 | $5.0M | $1.5M | +42.08% |
| Q1 2019 | 2019-03-31 | $4.0M | $239,000 | +6.32% |
| Q4 2018 | 2018-12-31 | $4.8M | $1.1M | +31.75% |
| Q3 2018 | 2018-09-30 | $4.5M | $753,000 | +20.31% |
| Q2 2018 | 2018-06-30 | $3.5M | $567,000 | +19.28% |
| Q1 2018 | 2018-03-31 | $3.8M | $1.2M | +46.40% |
| Q4 2017 | 2017-12-31 | $3.6M | −$707,000 | −16.38% |
| Q3 2017 | 2017-09-30 | $3.7M | $938,000 | +33.88% |
| Q2 2017 | 2017-06-30 | $2.9M | −$1.9M | −39.71% |
| Q1 2017 | 2017-03-31 | $2.6M | −$205,000 | −7.35% |
| Q4 2016 | 2016-12-31 | $4.3M | $786,000 | +22.26% |
| Q3 2016 | 2016-09-30 | $2.8M | −$926,000 | −25.06% |
| Q2 2016 | 2016-06-30 | $4.9M | $1.2M | +31.06% |
| Q1 2016 | 2016-03-31 | $2.8M | −$1.3M | −31.32% |
| Q4 2015 | 2015-12-31 | $3.5M | $370,000 | +11.71% |
| Q3 2015 | 2015-09-30 | $3.7M | $86,000 | +2.38% |
| Q2 2015 | 2015-06-30 | $3.7M | −$854,000 | −18.66% |
| Q1 2015 | 2015-03-31 | $4.1M | −$4,000 | −0.10% |
| Q4 2014 | 2014-12-31 | $3.2M | −$1.7M | −35.40% |
| Q3 2014 | 2014-09-30 | $3.6M | −$1.7M | −32.55% |
| Q2 2014 | 2014-06-30 | $4.6M | $505,000 | +12.40% |
| Q1 2014 | 2014-03-31 | $4.1M | −$65,000 | −1.57% |
| Q4 2013 | 2013-12-31 | $4.9M | −$670,000 | −12.04% |
| Q3 2013 | 2013-09-30 | $5.4M | $978,000 | +22.36% |
| Q2 2013 | 2013-06-30 | $4.1M | −$1.1M | −21.29% |
| Q1 2013 | 2013-03-31 | $4.1M | −$2.3M | −35.71% |
| Q4 2012 | 2012-12-31 | $5.6M | $683,000 | +14.00% |
| Q3 2012 | 2012-09-30 | $4.4M | $277,000 | +6.76% |
| Q2 2012 | 2012-06-30 | $5.2M | $739,000 | +16.67% |
| Q1 2012 | 2012-03-31 | $6.4M | $2.3M | +55.06% |
| Q4 2011 | 2011-12-31 | $4.9M | — | — |
| Q3 2011 | 2011-09-30 | $4.1M | $404,000 | +10.94% |
| Q2 2011 | 2011-06-30 | $4.4M | — | — |
| Q1 2011 | 2011-03-31 | $4.1M | — | — |
| Q3 2010 | 2010-09-30 | $3.7M | — | — |
Conmed capital expenditures (capex) trends
Over the last five fiscal years, Conmed's capital expenditures (capex) increased from $13.0M to $19.8M, a change of $6.8M. The latest reported quarter, Q2 2026, shows $2.9M.
What capital expenditures (CapEx) mean
Capital expenditures, commonly called CapEx, are cash investments in long-lived assets such as property, plants, equipment, infrastructure, and productive software. CapEx can support future growth or maintain existing operations, but it reduces current-period free cash flow.
SEC-reported capital expenditures
TickerStat standardizes cash payments for property, plant, equipment, and other productive assets reported in company SEC filings. When a filer reports separate qualifying CapEx components instead of a total, those components are combined for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Conmed source filings ↗